全文获取类型
收费全文 | 205篇 |
免费 | 31篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 25篇 |
妇产科学 | 1篇 |
基础医学 | 58篇 |
口腔科学 | 4篇 |
临床医学 | 16篇 |
内科学 | 40篇 |
皮肤病学 | 9篇 |
神经病学 | 6篇 |
特种医学 | 26篇 |
外科学 | 22篇 |
综合类 | 12篇 |
预防医学 | 8篇 |
眼科学 | 2篇 |
药学 | 6篇 |
肿瘤学 | 9篇 |
出版年
2023年 | 1篇 |
2022年 | 3篇 |
2021年 | 6篇 |
2020年 | 5篇 |
2018年 | 4篇 |
2017年 | 5篇 |
2015年 | 5篇 |
2014年 | 8篇 |
2013年 | 7篇 |
2012年 | 4篇 |
2011年 | 4篇 |
2010年 | 16篇 |
2009年 | 10篇 |
2008年 | 7篇 |
2007年 | 9篇 |
2006年 | 6篇 |
2005年 | 4篇 |
2004年 | 5篇 |
2003年 | 7篇 |
2002年 | 5篇 |
2001年 | 6篇 |
2000年 | 2篇 |
1999年 | 7篇 |
1998年 | 16篇 |
1997年 | 23篇 |
1996年 | 15篇 |
1995年 | 7篇 |
1994年 | 11篇 |
1993年 | 11篇 |
1992年 | 1篇 |
1991年 | 4篇 |
1990年 | 1篇 |
1989年 | 4篇 |
1988年 | 4篇 |
1986年 | 1篇 |
1985年 | 4篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1981年 | 1篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1975年 | 2篇 |
排序方式: 共有245条查询结果,搜索用时 15 毫秒
41.
Iron,HCV and the liver 总被引:9,自引:0,他引:9
K.P.Maier 《World journal of gastroenterology : WJG》1997,3(2):61-63
Iron,HCVandtheliverK.P.MaierSubjectheadingsIron;hepatitisCvirus;liver;hepatitisCIRONIronservesasanesentialmetalforthesurvival... 相似文献
42.
43.
Paulsson AK McMullen KP Peiffer AM Hinson WH Kearns WT Johnson AJ Lesser GJ Ellis TL Tatter SB Debinski W Shaw EG Chan MD 《中国神经肿瘤杂志》2013,(1):52-52
PURPOSE: We investigate the patterns of failure in the treatment of glioblastoma(GBM) based on clinical target volume(CTV) margin size,dose delivered to the site of initial failure,and the use of temozolomide and intensity-modulated radiotherapy(IMRT).METHODS: Between August 2000 and May 2010,161 patients with GBM were treated with radiotherapy with or without concurrent temozolomide.Patients were treated with CTV expansions that ranged from 5 to 20 mm using a shrinking field technique.Patterns of failure and time to progression and overall survival were compared based on CTV margin,use of temozolomide,and use of IMRT.Kaplan Meier analysis was used to estimate survival times,and χ test was used for comparison of cohorts.RESULTS: For patients treated with 5-,10-,and 15-to 20-mm CTV,79%,77%,and 86% experienced failures in the 60 Gy volume,respectively.Forty-eight percent,55%,and 66% of patients with 5-,10-,and 15-to 20-mm CTV experienced failures in the 46 Gy volume,respectively.There was no statistical difference between patients treated with 5-,10-,15-to 20-mm margins with regard to 60 Gy failure(P=0.76),46 Gy failure(P=0.51),or marginal failure(P=0.73).Eighty percent of patients receiving temozolomide experienced failures in the 60 Gy volume.There was no increased likelihood of marginal failures in patients receiving IMRT(P =0.97).CONCLUSIONS: Modern treatment techniques including use of concurrent temozolmide,limited CTV margin size,and IMRT have not greatly changed the patterns of failure of GBM. 相似文献
44.
With the Food and Drug Administration designation in 2017 of 3,4-methylenedioxymethamphetamine (MDMA) as a breakthrough therapy in post-traumatic stress disorder and psilocybin in treatment-resistant depression, psychedelic drugs have continued to garner the attention of researchers and clinicians for their promise of unmatched, rapid improvement in a multitude of psychiatric conditions. Classic psychedelic drugs including psilocybin, lysergic acid diethylamide, and ayahuasca, as well as non-classic drugs such as MDMA and ketamine, are currently being investigated for a potential therapeutic role in trauma, depressive disorders, and other psychopathologies. However, psilocybin and MDMA each have a functional profile well-suited for integration with psychotherapy. The present review focuses on psilocybin and MDMA in psychedelic-assisted therapy (PAT), as these studies compose most of the literature pool. In this review, we discuss the current and future uses of psychedelic drugs, with an emphasis on the role of MDMA and psilocybin in PAT in the setting of trauma and related comorbidities on the efficacy of psychedelic drugs across multiple psychiatric disorders. The article concludes with thoughts for future research, such as incorporating wearables and standardization of symptom scales, therapy styles, and assessment of adverse drug reactions. 相似文献
45.
和田地区不仅是新疆,而且是世界上最严重的碘缺乏区之一.由于碘的缺乏,1987年自治区组成碘缺乏病流行区预防小组,由各行专家,对严重碘缺乏地区的初期妊娠妇女、出生后1个月婴儿、1岁儿童、2岁儿童分成4组,进行口服补碘及土地灌溉加碘防治工作. 相似文献
46.
The field of gastroenterology has recently seen a surge in wearable technology to monitor physical activity, sleep quality, pain, and even gut activity. The past decade has seen the emergence of wearable devices including Fitbit, Apple Watch, AbStats, and ingestible sensors. In this review, we discuss current and future devices designed to measure sweat biomarkers, steps taken, sleep efficiency, gastric electrical activity, stomach pH, and intestinal contents. We also summarize several clinical studies to better understand wearable devices so that we may assess their potential benefit in improving healthcare while also weighing the challenges that must be addressed. 相似文献
47.
Temporomandibular joint injuries 总被引:2,自引:0,他引:2
The clinical and radiologic findings in 30 patients who sustained injuries to the temporomandibular joint (TMJ) were retrospectively analyzed. Imaging consisted of variable combinations of radiography, tomography, two-compartment arthrography, computed tomography, and magnetic resonance imaging and was performed 2 days to 24 months after injury. Indications for imaging included acquired and/or unstable occlusal disturbances, cephalalgia, facial pain, otalgia, TMJ pain, tinnitus, dizziness, hearing disturbance, masticatory dysfunction, and muscle atrophy. Radiologic findings included internal derangement of the TMJ meniscus, swelling of retrodiskal tissues, joint effusion, mandibular condyle and condylar neck fractures, osteochondritis dissecans, avascular necrosis, degenerative condylar remodeling, osteoarthritis, musculotendinous injuries, and atrophy of masticatory muscles. After imaging studies, seven patients underwent surgery, at which time imaging findings were confirmed; one patient underwent successful aspiration of a painful hemarthrosis. TMJ injuries may result in joint derangement, radiologically demonstrable joint degeneration, masticatory muscle dysfunction, pain, and progressive clinical disability. 相似文献
48.
49.
Erythropoietin and sexual dysfunction 总被引:7,自引:1,他引:6
Lawrence IG; Price DE; Howlett TA; Harris KP; Feehally J; Walls J 《Nephrology, dialysis, transplantation》1997,12(4):741-747
BACKGROUND: Erythropoietin (rHuEpo) therapy has been shown to improve
sexual function in the male dialysis population, with several studies
suggesting a direct effect upon endocrine function, as well as correction
of anaemia. Nevertheless many male dialysis patients receiving rHuEpo
continue to complain of sexual dysfunction. METHODS: At a dedicated renal
impotence clinic, 65 male dialysis patients were screened for endocrine
disturbances. Baseline serum sex hormones were compared between those
receiving and not receiving rHuEpo, using either the two-sample t test or
the Mann-Whitney U test, after assessing for normality. Results from four
patients were excluded on account of either medications (antiemetic
phenothiazines), hepatic dysfunction, or carcinomatosis. RESULTS:
Twenty-five patients (41.0%) were receiving rHuEpo, the recipients and
non-recipients being well matched for haemoglobin (10.19 +/- 0.29 vs 10.55
+/- 0.25 g/dl, n.s.), age (51.1 +/- 1.9 vs 53.6 +/- 2.1 years, n.s.) and
duration of sexual dysfunction (median, 3.0 vs 3.0 years, n.s.). The rHuEpo
recipients had a higher median creatinine (1090 vs 972 micromol/l, P <
0.02), but similar nutritional status to the non-recipients (albumin 41.0
vs 39.0 g/l, n.s.). The total duration of rHuEpo therapy was 0.85 +/- 0.14
years. Prolactin levels were similar in both the rHuEpo recipients and non-
recipients (440 vs 541 mu/l, n.s.), as were LH (11.0 vs 10.5 iu/l, n.s.)
and FSH (8.0 vs 6.5 iu/l, n.s.). However, there were significant elevations
of testosterone (19.8 +/- 1.3 vs 16.1 +/- 1.1 nmol/l, P < 0.05) and sex
hormone binding globulin (SHBG) (40.5 vs 26.0 nmol/l, P < 0.01), with a
trend toward elevated oestradiol (304 vs 248 pmol/l, P = 0.095) in the
rHuEpo-treated group. Forty-eight subjects (78.7%) received peritoneal
dialysis (PD), with the 19 rHuEpo recipients (39.6%) demonstrating
increased serum testosterone (21.0 +/- 1.5 vs 16.6 +/- 1.3 nmol/l, P <
0.05), SHBG (40.5 vs 26.5 nmol/l, P < 0.01), LH (15.0 vs 10.0 iu/l, P
< 0.01) and FSH (12.0 vs 5.3 iu/l, P < 0.05). These differences were
not demonstrated in the 13 haemodialysis (HD) subjects. CONCLUSIONS: Male
dialysis patients complaining of sexual dysfunction after correction of
anaemia with rHuEpo are characterized by higher levels of serum
testosterone and SHBG, but not suppression of hyperprolactinaemia or
hyperoestrogenism. Male PD subjects receiving rHuEpo also demonstrated
increased LH and FSH.
相似文献